Entries by Trethera

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

15th November 2021 in /by

Los Angeles, November 12, 2021— Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON). ON is a rare autoimmune disease where patients rapidly lose vision in one or both eyes with 1 in 10 patients never fully recovering their eyesight. TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK). […]

Trethera Doses First Patient in Landmark Clinical Trial for the Treatment of Solid Tumors With First-In-Class Drug TRE-515

14th October 2021 in /by

Los Angeles, October 15, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient has been treated with TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK). Trethera’s multi-site Phase 1 study will evaluate TRE-515 monotherapy in up […]

Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board

25th May 2021 in /by

Los Angeles, May 25, 2021 – Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancers and autoimmune diseases, is pleased to announce the appointment of renowned autoimmunity researcher Dr. Larry Steinman to its Scientific Advisory Board.  Dr. Steinman will be advising Trethera regarding TRE-515 development, a first-in-class compound with the potential to treat multiple sclerosis (MS) and other autoimmune neurologic diseases. […]

Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

19th April 2021 in /by

Los Angeles, April 19, 2021— Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has approved its TRE-515 investigational new drug (IND) application for the treatment of solid tumor malignancies.  Trethera will […]

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

16th March 2021 in /by

Los Angeles, March 16, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases announces that Frank Baxter has been appointed as special advisor. He will be advising Trethera and its board of directors on financing options including private equity, public […]

18 F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis

5th March 2021 in /by

Abstract: Brain-infiltrating leukocytes contribute to multiple sclerosis (MS) and autoimmune encephalomyelitis and likely play a role in traumatic brain injury, seizure, and stroke. Brain-infiltrating leukocytes are also primary targets for MS disease-modifying therapies. However, no method exists for noninvasively visualizing these cells in a living organism. 1-(2′-deoxy-2′-18F-fluoroarabinofuranosyl) cytosine (18F-FAC) is a PET radiotracer that measures […]

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

24th February 2021 in /by

Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing.  Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

7th January 2021 in /by

Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board

8th December 2020 in /by

Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]

Trethera Announces U.S. Patent Application Filed for TRE-515, Extending Major Markets Exclusivity until 2041

2nd November 2020 in /by

Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515.  If granted, […]